Sandra and Edward Meyer Cancer Center

You are here


The Treatment Paradigm for Gastrointestinal Cancers

Wednesday, February 17, 2016

BBI608 is currently under investigation via the phase III BRIGHTER trial as a second-line treatment for patients with gastric and gastroesophageal junction cancer who have previously undergone platinum and fluoropyrimidine-based chemotherapy. The study launched in June 2014 and is seeking to enroll 700 patients who experience clinical or radiologic disease progression during first-line treatment for unresectable or metastatic disease or ≥6 months after finishing therapy.

Manish A. Shah, M.D., Bartlett Associate Professor of GI Oncology, talks to Targeted Oncology about how BBI608 might fit into the treatment paradigm for gastric and gastroesophageal junction cancer. Shah says as more treatments become available, oncologists need to consider the order in which they give patients treatments. He adds that not all gastric cancers are the same, so identifying which cancers would be best treated by a PD-1 inhibitor and which would be best treated by a stem cell inhibitor is crucial.